Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-08-24 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
第五届董事会第八次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is an announcement of resolutions from the fifth board of directors' eighth meeting of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) held on August 22, 2020. It mentions the approval of the company's 2020 semi-annual report and a special report on the use of raised funds. However, the document itself does not contain the full semi-annual report or detailed financial statements; instead, it directs readers to the official disclosure website (巨潮资讯网) for the full report. The document is relatively short (1056 characters) and serves as a formal announcement of board meeting decisions rather than the report itself. According to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA) rather than the actual Interim/Quarterly Report (IR).
2020-08-24 Chinese
2020年半年度报告提示性公告
Report Publication Announcement Classification · 100% confidence The document is very short (392 characters) and is titled as a "2020 半年度报告提示性公告" which translates to "2020 Semi-Annual Report Reminder Announcement." It states that the company's 2020 semi-annual report and its summary were disclosed on August 25, 2020, on the designated information disclosure website. The document does not contain the actual financial data or the report itself but is an announcement directing investors to the full report elsewhere. According to the MENU VS MEAL RULE, such a short document that announces the availability of a report without including the report itself should be classified as a Report Publication Announcement (RPA).
2020-08-24 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "康芝药业股份有限公司 2020 年半年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2020 Semi-Annual Report Full Text." It contains detailed sections including company overview, financial data, business summary, risk factors, and financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial figures, business analysis, and operational details for the half-year period ending 2020. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2020
2020-08-24 Chinese
2020年半年度募集资金存放与使用情况专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2020 年半年度募集资金存放与使用情况专项报告" which translates to "2020 Half-Year Special Report on the Deposit and Use of Raised Funds". It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The content details the actual raised funds, their management, usage, cash management, and investment projects related to the raised funds for the half-year period ending June 30, 2020. It includes detailed financial data and tables about the raised funds usage and investment projects, indicating it is a comprehensive report for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement or a certification but a detailed report with substantive financial data and analysis for the half-year period. Therefore, the appropriate classification is IR (Interim / Quarterly Report). H1 2020
2020-08-24 Chinese
第五届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2020 semi-annual report and a special report on the use of raised funds. It includes voting results and assurances about the accuracy and completeness of the reports. The document itself does not contain the full semi-annual report or detailed financial statements but rather announces the approval and review of these reports by the Supervisory Board. The document length is short (1029 characters) and serves as an official announcement of meeting resolutions rather than the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for announcements and compliance-related disclosures that do not contain full financial reports.
2020-08-24 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2020 年半年度报告摘要" which translates to "2020 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses operational highlights, R&D progress, investment activities, and management commentary on the business environment and company strategy. The length of the document (7687 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.